SCHEMBL21564532

SCHEMBL21564532

CC(C)(C)OC(=O)N1CCN(c2nc(CCC=O)cn(COCC[Si](C)(C)C)c2=O)CC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OGFRL1 Q5TC84 1/20 0.35
GPR119 Q8TDV5 4/20 0.35
ACHE P22303 2/20 0.35
GBA1 P04062 2/20 0.34
HTT P42858 1/20 0.34
ATM Q13315 1/20 0.34
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TLR9 Q9NR96 1/20 0.34
PIK3CA P42336 2/20 0.33
GRIA1 P42261 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
KIT P10721 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21564531 0.88 ALDH1A1 (0.38) OPRM1OPRD1OGFRL1GPR119ACHE
SCHEMBL21553060 0.88 KLKB1 (0.33)
SCHEMBL21552949 0.85 ALDH1A1 (0.36) OPRM1OPRD1OGFRL1GPR119ACHE
SCHEMBL21564653 0.84 GBA1 (0.38) OPRM1OPRD1OGFRL1GPR119ACHE
SCHEMBL21553013 0.84 MEN1 (0.34) ALDH1A1
SCHEMBL21553059 0.84 DGAT1 (0.31)
SCHEMBL21553037 0.83 ALDH1A1 (0.33) HTTALDH1A1
SCHEMBL21564568 0.83 ALDH1A1 (0.33) HTTALDH1A1
SCHEMBL21553116 0.82 PIK3CA (0.36) ALDH1A1PIK3CA
SCHEMBL26031619 0.81 DGAT1 (0.33) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A OPRM1 4544/4885OPRD1 4028/4885OGFRL1 2860/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A OPRM1 4459/4885OPRD1 3959/4885OGFRL1 2604/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A OPRM1 4544/4885OPRD1 4028/4885OGFRL1 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.